OTCMKTS:MITPF Mithra Pharmaceuticals (MITPF) Stock Price, News & Analysis $6.75 0.00 (0.00%) As of 06/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Mithra Pharmaceuticals Stock (OTCMKTS:MITPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mithra Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.75▼$6.7550-Day Range$6.75▼$6.7552-Week Range$6.75▼$7.75VolumeN/AAverage Volume1,600 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mithra Pharmaceuticals is a Belgian biopharmaceutical company dedicated to the development and commercialization of products for women’s health. The company focuses on innovative solutions in contraception, menopause care, and hormone replacement therapy, leveraging its expertise in steroidal and non-steroidal compounds. Mithra’s research efforts center on selective estrogen receptor modulators and tissue-selective estrogen complexes designed to offer improved safety and tolerability profiles compared with traditional hormonal therapies. Among its approved offerings is Estelle, a combined oral contraceptive that incorporates estetrol, a naturally occurring fetal estrogen, which is under registration in multiple European countries. Mithra’s pipeline includes novel candidates for menopause symptom relief and treatments for endometriosis, with several programs progressing through clinical development. The company also pursues strategic partnerships and licensing agreements to expand the reach of its contraceptive and hormone therapy products across global markets. Founded in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates research and manufacturing facilities in Europe and maintains a commercial presence in key markets. The company’s team brings together expertise in medicinal chemistry, endocrinology and regulatory affairs to advance its portfolio. Through ongoing collaborations and clinical research, Mithra aims to address unmet needs in women’s health by delivering safer, science-driven therapies.AI Generated. May Contain Errors. Read More Receive MITPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mithra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MITPF Stock News HeadlinesMithra Pharmaceuticals S.A.EO-Obl.Conv. Bonds 2020(25) BondNovember 29, 2025 | markets.businessinsider.comMithra Mandali OTT Release: When And Where To Watch South Comedy Drama Starring Priyadarshi PulikondaNovember 6, 2025 | msn.comSpaceX will crumble without these 5 companiesThe SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.June 20 at 1:00 AM | InvestPub (Ad)Mithra Mandali OTT Release: Where To Watch Priyadarshi, Vennela Kishore's Comedy FilmNovember 5, 2025 | msn.comMithra Mandali to hold paid premieres a day ahead of releaseOctober 14, 2025 | msn.comMithra Mandali Teaser: Priyadarshi and Vennela Kishore Join Forces for a Comedic DelightOctober 7, 2025 | msn.comYoung Mithra’s amazing 62km cycle ride around the Rugby area raises funds for important causesJuly 8, 2025 | msn.comFirst Look of Priyadarshi-starrer Mithra Mandali unveiledJune 7, 2025 | msn.comSee More Headlines MITPF Stock Analysis - Frequently Asked Questions How have MITPF shares performed this year? Mithra Pharmaceuticals' stock was trading at $6.75 on January 1st, 2026. Since then, MITPF stock has increased by 0.0% and is now trading at $6.75. How do I buy shares of Mithra Pharmaceuticals? Shares of MITPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MITPF CIKN/A Webwww.mithra.com Phone32 4 349 28 22FaxN/AEmployees270Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:MITPF) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mithra Pharmaceuticals SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Mithra Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.